Role of Non-contrast MDCT in the Assessment of Upper Urinary Tract Calculi Post ESWL to Predict Its Success Rate

Sponsor
Assiut University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05592457
Collaborator
(none)
55
1
24.5
2.2

Study Details

Study Description

Brief Summary

Urinary stones are a common disease affecting one in 11 people . Their clinical presentation varies from being silent to severe loin pain owing to urinary obstruction. Currently, ESWL is the treatment of choice for most renal calculi ⩽30 mm, with success rates of 60-99%. Although many treatment options exist, ESWL has the advantages of simplicity and non-invasiveness. In contrast, failure of a first ESWL attempt requires a follow-up ESWL procedure, or an alternative procedure, both of which increase medical costs.

Advancements in imaging have significantly contributed to this process. In the mid- 1990s, computed tomography (CT) began to replace intravenous urography (IVU), abdominal films (KUB), and ultrasound (US) in stone diagnosis. Studies demonstrated that CT had superior sensitivity and specificity for stone diagnosis compared to the aforementioned modalities. Now non-contrast multidetector CT (NC-MDCT) is the gold standard for the detection of urinary system calculi. CT is also clinically useful as it can show alternate renal and non-renal pathology if present.

Many factors have been reported to predict ESWL outcome, such as skin-to-stone distance (SSD), stone size, stone location, multiplicity, the energy used, and Hounsfield Unit (HU) values measured by non-contrast computed tomography (NCCT).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: MSCT

Detailed Description

Excellent fragmentation results are produced using ESWL. However, the retention of post-ESWL fragments in the kidney continues to be a significant medical issue. Only 32% of calcium stone patients in research were found to remain stone-free for 12 months following ESWL, according to the results. As a result, it appears that fragment growth and persistence are frequent after ESWL [10].

The first ESWL residual that is accessible must undergo a thorough stone analysis to properly carry out the subsequent treatments to prevent relapse or recurrent stone because stone-free rates after ESWL are directly connected to stone placement, size, number, and composition

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
55 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Role of Non-contrast MDCT in the Assessment of Upper Urinary Tract Calculi Post ESWL to Predict Its Success Rate
Actual Study Start Date :
Oct 15, 2022
Anticipated Primary Completion Date :
Oct 30, 2023
Anticipated Study Completion Date :
Oct 30, 2024

Outcome Measures

Primary Outcome Measures

  1. ct follow up during swl [3 weeks]

    Correlation between the stone density before and during ESWL sessions to determine if this predicts the success prevent new ESWL.

  2. stone Hounsfield [3weeks]

    Determine the role of the density of the residual stone fragments in the prediction of the complication during ESWL.

Secondary Outcome Measures

  1. density of stone and other factors [3weeks]

    Correlate between stone density and other factors in the prediction of the success of ESWL.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • patients older than 18 years.

  • stone size up to 25 mm for renal pelvic stones and up to 15 mm for upper ureteric stones.

  • SSD < 11 cm.

Exclusion Criteria:
  • any patient with contraindications to ESWL as

  • uncontrolled urinary infection.

  • clotting alterations.

  • aortic or renal artery aneurysm.

  • pregnancy.

  • serious skeletal malformations.

  • serious obesity and or contraindications to CT as pregnancy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assiut University Hospital Assiut Egypt 11751

Sponsors and Collaborators

  • Assiut University

Investigators

  • Study Director: gehan sayed, MD, Assiut University
  • Study Director: Doria mohamed, md, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dina Essam, principle investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT05592457
Other Study ID Numbers:
  • MDCT in ESWL
First Posted:
Oct 24, 2022
Last Update Posted:
Oct 25, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 25, 2022